But now more Medicare patients may be able to access semaglutide for weight loss. This spring, the CMS said it would cover the costs of Novo Nordisk’s Wegovy for some people with a history of ...

According to a study published today in Annals of Internal Medicine, expanding Medicare coverage for semaglutide could make millions of older Americans newly eligible for the drug, but with the ...

For continued coverage of its semaglutide medicines under Medicare, NVO has until Feb. 28, 2025, to decide if it will participate in negotiations or pay a large tax on U.S. sales of the drugs.

Around one in seven Medicare beneficiaries with a high body mass index (BMI) may be newly eligible for semaglutide treatment after Medicare allowed Part D plans to cover the drug for patients with ...

With Medicare now covering semaglutide for people with obesity and cardiovascular disease who don't have diabetes, a study looks at who that might include, depending on what cutoffs prescription ...

Close to 2.3 million seniors in Medicare are using the semaglutide medications, branded as Ozempic, Rybelsus and Wegovy by Novo Nordisk. Medicare says that the drug added up to more than $14 ...

Medicare coverage for Ozempic is not the same as Wegovy. Wegovy contains the same active ingredient as Ozempic, semaglutide, but it is FDA approved to help with weight loss. Medicare can cover ...

Should Medicare and Medicaid eventually cover new weight loss drugs such as Ozempic and Wegovy? This week, Audacy took a look at the issue with Dr. Anand Parekh of the Bipartisan Policy Center.

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

If all newly eligible patients received semaglutide, spending in Medicare’s Part D prescription drug benefit could increase by $34 billion to $145 billion each year, according to the study.